A letter published in The New England Journal of Medicine last week implied that Celgene Corp.'s Thalomid thalidomide was responsible for the high level of deep vein thrombosis (DVT) seen in a suspended Phase II trial of the drug in combination with doxorubicin and dexamethasone to treat multiple myeloma. But according to the company, the main culprits are both doxorubicin and the disease itself.

Investigators at the Sloan-Kettering Cancer Center in New York reported that 4 of 15 patients (27%) with